Heart, kidney and left ventricular assist device: a complex trio.
AKI
LVAD
heart failure
mechanical circulatory assist device
renal failure
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
24
07
2021
received:
10
06
2021
accepted:
03
08
2021
pubmed:
5
8
2021
medline:
17
3
2022
entrez:
4
8
2021
Statut:
ppublish
Résumé
Heart failure (HF) is a complex syndrome affecting the whole body, kidneys included. The left ventricular assist device (LVAD) is a valid option for patients with very severe HF. Focusing on renal function, LVAD implantation could theoretically reverse the detrimental effects of HF syndrome on kidneys. However, implanting an LVAD is a high-risk surgical procedure, and LVAD patients have higher risk of bleeding, device thrombosis, strokes, renal impairment, multi-organ failure and infections. Furthermore, an LVAD has its own particular effects on the renal system. In this review, we provide a comprehensive overview of the complex interaction between LVAD and the kidneys from the pathophysiological and clinical perspectives. An analysis of the different effects of pulsatile-flow and continuous-flow LVAD is provided. Despite their limitations, creatinine-based estimated glomerular filtration rate (eGFR) formulas help to stratify patients by their post-LVAD placement prognosis. Poor basal renal function, the onset of acute kidney injury or the need for renal replacement therapy after LVAD implantation negatively influences a patient's prognosis. LVAD can also prompt an improvement in renal function, however, with some counterintuitive effects on a patient's prognosis. It is still hard to say whether different trends in eGFR depend on different renal conditions before LVAD placement, on a patient's better overall status or on a particular patient management strategy before and/or after the device's implantation. Steps should be taken to solve this question because finding the best candidates for LVAD implantation is of paramount importance to ensure the best outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Heart failure (HF) is a complex syndrome affecting the whole body, kidneys included. The left ventricular assist device (LVAD) is a valid option for patients with very severe HF. Focusing on renal function, LVAD implantation could theoretically reverse the detrimental effects of HF syndrome on kidneys. However, implanting an LVAD is a high-risk surgical procedure, and LVAD patients have higher risk of bleeding, device thrombosis, strokes, renal impairment, multi-organ failure and infections. Furthermore, an LVAD has its own particular effects on the renal system.
METHODS
METHODS
In this review, we provide a comprehensive overview of the complex interaction between LVAD and the kidneys from the pathophysiological and clinical perspectives. An analysis of the different effects of pulsatile-flow and continuous-flow LVAD is provided.
RESULTS
RESULTS
Despite their limitations, creatinine-based estimated glomerular filtration rate (eGFR) formulas help to stratify patients by their post-LVAD placement prognosis. Poor basal renal function, the onset of acute kidney injury or the need for renal replacement therapy after LVAD implantation negatively influences a patient's prognosis. LVAD can also prompt an improvement in renal function, however, with some counterintuitive effects on a patient's prognosis.
CONCLUSION
CONCLUSIONS
It is still hard to say whether different trends in eGFR depend on different renal conditions before LVAD placement, on a patient's better overall status or on a particular patient management strategy before and/or after the device's implantation. Steps should be taken to solve this question because finding the best candidates for LVAD implantation is of paramount importance to ensure the best outcomes.
Substances chimiques
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13662Informations de copyright
© 2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200.
McAlister FA, Ezekowitz J, Tarantini L, et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula. Circ Heart Fail. 2012;5:309-314.
Ronco C, Bellasi A, Di Lullo L. Cardiorenal syndrome: an overview. Adv Chronic Kidney Dis. 2018;25:382-390.
Zoccali C, Goldsmith D, Agarwal R, et al. The complexity of the cardio-renal link: taxonomy, syndromes, and diseases. Kidney Int Suppl. 2011;2011(1):2-5.
Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation. 2010;121:2592-2600.
Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671-678.
Filsoufi F, Rahmanian PB, Castillo JG, Chikwe J, Carpentier A, Adams DH. Early and late outcomes of cardiac surgery in patients with moderate to severe preoperative renal dysfunction without dialysis. Interact Cardiovasc Thorac Surg. 2008;7:90-95.
Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.
Rogers JG, Pagani FD, Tatooles AJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med. 2017;376:451-460.
Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435-1443.
Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885-896.
Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 2009;54:312-321.
Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016;35:1-23.
Kirklin JK, Pagani FD, Goldstein DJ, et al. American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support. J Thorac Cardiovasc Surg. 2020;159:865-896.
Potapov EV, Antonides C, Crespo-Leiro MG, et al. 2019 EACTS Expert Consensus on long-term mechanical circulatory support. Eur J Cardiothorac Surg. 2019;56:230-270.
Cowger J, Sundareswaran K, Rogers JG, et al. Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. J Am Coll Cardiol. 2013;61:313-321.
Russell SD, Miller LW, Pagani FD. Advanced heart failure: a call to action. Congest Heart Fail. 2008;14:316-321.
Teuteberg JJ, Cleveland JC Jr, Cowger J, et al. The Society of Thoracic Surgeons Intermacs 2019 annual report: the changing landscape of devices and indications. Ann Thorac Surg. 2020;109:649-660.
de By T, Mohacsi P, Gahl B, et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardio-Thoracic Surgery (EACTS): second report. Eur J Cardiothorac Surg. 2018;53:309-316.
Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53:582-588.
Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-596.
Patibandla PK, Rajasekaran NS, Shelar SB, Giridharan GA, Litovsky SH, Sethu P. Evaluation of the effect of diminished pulsatility as seen in continuous flow ventricular assist devices on arterial endothelial cell phenotype and function. J Heart Lung Transplant. 2016;35:930-932.
Nishimura T, Tatsumi E, Takaichi S, et al. Prolonged nonpulsatile left heart bypass with reduced systemic pulse pressure causes morphological changes in the aortic wall. Artif Organs. 1998;22:405-410.
Cornwell WK 3rd, Tarumi T, Stickford A, et al. Restoration of pulsatile flow reduces sympathetic nerve activity among individuals with continuous-flow left ventricular assist devices. Circulation. 2015;132:2316-2322.
Markham DW, Fu Q, Palmer MD, et al. Sympathetic neural and hemodynamic responses to upright tilt in patients with pulsatile and nonpulsatile left ventricular assist devices. Circ Heart Fail. 2013;6:293-299.
Welp H, Rukosujew A, Tjan TD, et al. Effect of pulsatile and non-pulsatile left ventricular assist devices on the renin-angiotensin system in patients with end-stage heart failure. Thorac Cardiovasc Surg. 2010;58(Suppl 2):S185-S188.
Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14:30-38.
Ootaki C, Yamashita M, Ootaki Y, et al. Reduced pulsatility induces periarteritis in kidney: role of the local renin-angiotensin system. J Thorac Cardiovasc Surg. 2008;136:150-158.
Witman MA, Garten RS, Gifford JR, et al. Further peripheral vascular dysfunction in heart failure patients with a continuous-flow left ventricular assist device: the role of pulsatility. JACC Heart Fail. 2015;3:703-711.
Segura AM, Gregoric I, Radovancevic R, Demirozu ZT, Buja LM, Frazier OH. Morphologic changes in the aortic wall media after support with a continuous-flow left ventricular assist device. J Heart Lung Transplant. 2013;32:1096-1100.
Amir O, Radovancevic B, Delgado RM 3rd, et al. Peripheral vascular reactivity in patients with pulsatile vs axial flow left ventricular assist device support. J Heart Lung Transplant. 2006;25:391-394.
Purohit SN, Cornwell WK 3rd, Pal JD, Lindenfeld J, Ambardekar AV. Living without a pulse: the vascular implications of continuous-flow left ventricular assist devices. Circ Heart Fail. 2018;11:e004670.
Brisco MA, Kimmel SE, Coca SG, et al. Prevalence and prognostic importance of changes in renal function after mechanical circulatory support. Circ Heart Fail. 2014;7:68-75.
Sandner SE, Zimpfer D, Zrunek P, et al. Renal function after implantation of continuous versus pulsatile flow left ventricular assist devices. J Heart Lung Transplant. 2008;27:469-473.
Quader M, Goodreau AM, Johnson RM, Wolfe LG, Feldman GM. Impact of renal function recovery utilizing left ventricular assist device support. J Card Surg. 2020;35:100-107.
Sandner SE, Zimpfer D, Zrunek P, et al. Renal function and outcome after continuous flow left ventricular assist device implantation. Ann Thorac Surg. 2009;87:1072-1078.
Borgi J, Tsiouris A, Hodari A, Cogan CM, Paone G, Morgan JA. Significance of postoperative acute renal failure after continuous-flow left ventricular assist device implantation. Ann Thorac Surg. 2013;95:163-169.
Hasin T, Topilsky Y, Schirger JA, et al. Changes in renal function after implantation of continuous-flow left ventricular assist devices. J Am Coll Cardiol. 2012;59:26-36.
Schmack B, Grossekettler L, Weymann A, et al. Prognostic relevance of hemodialysis for short-term survival in patients after LVAD implantation. Sci Rep. 2018;8:8546.
Pasrija C, Tran D, George P, et al. Left ventricular assist device implantation may be feasible in appropriately selected patients with severe renal insufficiency. J Thorac Cardiovasc Surg. 2020;159:1307-1319.e2.
Kirklin JK, Naftel DC, Kormos RL, et al. Quantifying the effect of cardiorenal syndrome on mortality after left ventricular assist device implant. J Heart Lung Transplant. 2013;32(12):1205-1213. https://doi.org/10.1016/j.healun.2013.09.001
Muslem R, Caliskan K, Akin S, et al. Acute kidney injury and 1-year mortality after left ventricular assist device implantation. J Heart Lung Transplant. 2018;37:116-123.
Grodin JL, Drazner MH, Dupont M, et al. A disproportionate elevation in right ventricular filling pressure, in relation to left ventricular filling pressure, is associated with renal impairment and increased mortality in advanced decompensated heart failure. Am Heart J. 2015;169:806-812.
Kormos RL, Teuteberg JJ, Pagani FD, et al. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg. 2010;139:1316-1324.
de Nattes T, Litzler PY, Gay A, Nafeh-Bizet C, François A, Guerrot D. Hemolysis induced by Left Ventricular Assist Device is associated with proximal tubulopathy. PLoS One. 2020;15:e0242931.
Hasin T, Deo S, Maleszewski JJ, et al. The role of medical management for acute intravascular hemolysis in patients supported on axial flow LVAD. ASAIO J. 2014;60:9-14.
Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380:756-766.
Lagny MG, Jouret F, Koch JN, et al. Incidence and outcomes of acute kidney injury after cardiac surgery using either criteria of the RIFLE classification. BMC Nephrol. 2015;16:76.
Kirklin JK, Naftel DC, Pagani FD, et al. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant. 2015;34:1495-1504.
Yalcin YC, Bunge JJH, Guven G, et al. Acute kidney injury following left ventricular assist device implantation: contemporary insights and future perspectives. J Heart Lung Transplant. 2019;38:797-805.
Ono M, Joshi B, Brady K, et al. Cerebral blood flow autoregulation is preserved after continuous-flow left ventricular assist device implantation. J Cardiothorac Vasc Anesth. 2012;26:1022-1028.
Anjum A, Kurihara C, Critsinelis A, et al. Acute kidney injury after implantation of a left ventricular assist device: a comparison of axial-flow (HeartMate II) and centrifugal-flow (HeartWare HVAD) devices. J Artif Organs. 2018;21:285-292.
Critsinelis A, Kurihara C, Volkovicher N, et al. Model of End-Stage Liver Disease-eXcluding International Normalized Ratio (MELD-XI) scoring system to predict outcomes in patients who undergo left ventricular assist device implantation. Ann Thorac Surg. 2018;106:513-519.
Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;53:961-973.
Kaltenmaier B, Pommer W, Kaufmann F, Hennig E, Molzahn M, Hetzer R. Outcome of patients with ventricular assist devices and acute renal failure requiring renal replacement therapy. ASAIO J. 2000;46:330-333.
Genovese EA, Dew MA, Teuteberg JJ, et al. Early adverse events as predictors of 1-year mortality during mechanical circulatory support. J Heart Lung Transplant. 2010;29:981-988.
Evans RG, Ince C, Joles JA, et al. Haemodynamic influences on kidney oxygenation: clinical implications of integrative physiology. Clin Exp Pharmacol Physiol. 2013;40:106-122.
Matejovic M, Ince C, Chawla LS, et al. Renal hemodynamics in AKI. In search of new treatment targets. J Am Soc Nephrol. 2016;27:49-58.
Legrand M, Mik EG, Johannes T, Payen D, Ince C. Renal hypoxia and dysoxia after reperfusion of the ischemic kidney. Mol Med. 2008;14:502-516.
Munshi R, Hsu C, Himmelfarb J. Advances in understanding ischemic acute kidney injury. BMC Med. 2011;9:11.
Moore JP, Dyson A, Singer M, Fraser J. Microcirculatory dysfunction and resuscitation: why, when, and how. Br J Anaesth. 2015;115:366-375.
Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury. Clin Immunol. 2009;130:41-50.
Wu X, Zhang W, Ren H, Chen X, Xie J, Chen N. Diuretics associated acute kidney injury: clinical and pathological analysis. Ren Fail. 2014;36:1051-1055.
Goldstein SL. Medication-induced acute kidney injury. Curr Opin Crit Care. 2016;22:542-545.
Frazier OH, Myers TJ, Westaby S, Gregoric ID. Clinical experience with an implantable, intracardiac, continuous flow circulatory support device: physiologic implications and their relationship to patient selection. Ann Thorac Surg. 2004;77:133-142.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8(4):R204-R212. https://doi.org/10.1186/cc2872
Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31.
Alba AC, Rao V, Ivanov J, Ross HJ, Delgado DH. Predictors of acute renal dysfunction after ventricular assist device placement. J Card Fail. 2009;15:874-881.
Naik A, Akhter SA, Fedson S, Jeevanandam V, Rich JD, Koyner JL. Acute kidney injury and mortality following ventricular assist device implantation. Am J Nephrol. 2014;39:195-203.
Sumida M, Doi K, Kinoshita O, et al. Perioperative plasma neutrophil gelatinase-associated lipocalin measurement in patients who undergo left ventricular assist device implantation surgery. Circ J. 2014;78:1891-1899.
Go PH, Hodari A, Nemeh HW, et al. Effect of preoperative albumin levels on outcomes in patients undergoing left ventricular device implantation. ASAIO J. 2015;61:734-737.
Kurihara C, Critsinelis AC, Kawabori M, et al. Frequency and consequences of right-sided heart failure after continuous-flow left ventricular assist device implantation. Am J Cardiol. 2018;121:336-342.
Baxter RD, Tecson KM, Still S, et al. Predictors and impact of right heart failure severity following left ventricular assist device implantation. J Thorac Dis. 2019;11:S864-s870.
Macedo E, Bouchard J, Soroko SH, et al. Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. Crit Care. 2010;14:R82.
Brisco MA, Hale A, Heyward DP, et al. Decreased creatinine production in heart failure patients undergoing LVAD placement leads to overestimates of renal function. J Card Fail. 2014;20:S34.
Srisawat N, Kellum JA. The role of biomarkers in acute kidney injury. Crit Care Clin. 2020;36(1):125-140. https://doi.org/10.1016/j.ccc.2019.08.010
de Geus HR, Betjes MG, Bakker J. Biomarkers for the prediction of acute kidney injury: a narrative review on current status and future challenges. Clin Kidney J. 2012;5:102-108.
Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73:1008-1016.
Pronschinske KB, Qiu S, Wu C, et al. Neutrophil gelatinase-associated lipocalin and cystatin C for the prediction of clinical events in patients with advanced heart failure and after ventricular assist device placement. J Heart Lung Transplant. 2014;33:1215-1222.
Kamboj M, Kazory A. Left ventricular assist device and the kidney: getting to the heart of the matter. Blood Purif. 2019;48:289-298.
Hebert K, Dias A, Delgado MC, et al. Epidemiology and survival of the five stages of chronic kidney disease in a systolic heart failure population. Eur J Heart Fail. 2010;12:861-865.
Muslem R, Caliskan K, Akin S, et al. Pre-operative proteinuria in left ventricular assist devices and clinical outcome. J Heart Lung Transplant. 2018;37:124-130.
Biteker M, Dayan A, Tekkeşin A, et al. Incidence, risk factors, and outcomes of perioperative acute kidney injury in noncardiac and nonvascular surgery. Am J Surg. 2014;207:53-59.
Chen KP, Cavender S, Lee J, et al. Peripheral edema, central venous pressure, and risk of AKI in critical illness. Clin J Am Soc Nephrol. 2016;11:602-608.
Soliman OII, Akin S, Muslem R, et al. Derivation and validation of a novel right-sided heart failure model after implantation of continuous flow left ventricular assist devices: the EUROMACS (European Registry for Patients with Mechanical Circulatory Support) Right-Sided Heart Failure Risk Score. Circulation. 2018;137:891-906.
Coca SG, Garg AX, Swaminathan M, et al. Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery. Nephrol Dial Transplant. 2013;28:2787-2799.
Nigwekar SU, Kandula P, Hix JK, Thakar CV. Off-pump coronary artery bypass surgery and acute kidney injury: a meta-analysis of randomized and observational studies. Am J Kidney Dis. 2009;54:413-423.
Okusa MD. The inflammatory cascade in acute ischemic renal failure. Nephron. 2002;90:133-138.
Kumar AB, Suneja M. Cardiopulmonary bypass-associated acute kidney injury. Anesthesiology. 2011;114:964-970.
Karkouti K, Wijeysundera DN, Yau TM, et al. Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation. 2009;119:495-502.
Garg AX, Badner N, Bagshaw SM, et al. Safety of a restrictive versus liberal approach to red blood cell transfusion on the outcome of AKI in patients undergoing cardiac surgery: a randomized clinical trial. J Am Soc Nephrol. 2019;30:1294-1304.
Tecson KM, Lima B, Lee AY, et al. Determinants and outcomes of vasoplegia following left ventricular assist device implantation. J Am Heart Assoc. 2018;7(11):e008377. https://doi.org/10.1161/JAHA.117.008377
de Waal EEC, van Zaane B, van der Schoot MM, et al. Vasoplegia after implantation of a continuous flow left ventricular assist device: incidence, outcomes and predictors. BMC Anesthesiol. 2018;18:185.
de By TM, Mohacsi P, Gummert J, et al. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): first annual report. Eur J Cardiothorac Surg. 2015;47:770-776;discussion 776-7.
Topkara VK, Dang NC, Barili F, et al. Predictors and outcomes of continuous veno-venous hemodialysis use after implantation of a left ventricular assist device. J Heart Lung Transplant. 2006;25:404-408.
Demirozu ZT, Etheridge WB, Radovancevic R, Frazier OH. Results of HeartMate II left ventricular assist device implantation on renal function in patients requiring post-implant renal replacement therapy. J Heart Lung Transplant. 2011;30:182-187.
Rabindranath KS, Adams J, MacLeod AM, Muirhead N. Intermittent versus continuous renal replacement therapy for acute renal failure in adults. Cochrane Database Syst Rev. 2007:CD003773. https://doi.org/10.1002/14651858.CD003773.pub3
Topkara VK, Coromilas EJ, Garan AR, et al. Preoperative proteinuria and reduced glomerular filtration rate predicts renal replacement therapy in patients supported with continuous-flow left ventricular assist devices. Circ Heart Fail. 2016;9(12):e002897. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002897
Kirklin JK, Pagani FD, Kormos RL, et al. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. J Heart Lung Transplant. 2017;36:1080-1086.
Butler J, Geisberg C, Howser R, et al. Relationship between renal function and left ventricular assist device use. Ann Thorac Surg. 2006;81:1745-1751.
Silver SA, Long J, Zheng Y, et al. Outcomes after left ventricular assist device implantation in patients with acute kidney injury. J Thorac Cardiovasc Surg. 2020;159:477-486.e3.
Walther CP, Winkelmayer WC, Niu J, et al. Acute kidney injury with ventricular assist device placement: national estimates of trends and outcomes. Am J Kidney Dis. 2019;74:650-658.
Bos MJ, Koudstaal PJ, Hofman A, Breteler MM. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. Stroke. 2007;38:3127-3132.
O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension. 2005;46(1):200-204. https://doi.org/10.1161/01.HYP.0000168052.00426.65
Mezzano D, Tagle R, Panes O, et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost. 1996;76:312-321.
Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3:1526-1533.
Ziv O, Dizon J, Thosani A, Naka Y, Magnano AR, Garan H. Effects of left ventricular assist device therapy on ventricular arrhythmias. J Am Coll Cardiol. 2005;45:1428-1434.
Healy AH, Stehlik J, Edwards LB, McKellar SH, Drakos SG, Selzman CH. Predictors of 30-day post-transplant mortality in patients bridged to transplantation with continuous-flow left ventricular assist devices-an analysis of the International Society for Heart and Lung Transplantation Transplant Registry. J Heart Lung Transplant. 2016;35:34-39.
Arnaoutakis GJ, George TJ, Kilic A, et al. Risk factors for early death in patients bridged to transplant with continuous-flow left ventricular assist devices. Ann Thorac Surg. 2012;93:1549-1554; discussion 1555.
Habib PJ, Patel PC, Hodge D, et al. Pre-orthotopic heart transplant estimated glomerular filtration rate predicts post-transplant mortality and renal outcomes: an analysis of the UNOS database. J Heart Lung Transplant. 2016;35:1471-1479.
Cochrane AB, Lyster H, Lindenfeld J, et al. Report from the 2018 consensus conference on immunomodulating agents in thoracic transplantation: access, formulations, generics, therapeutic drug monitoring, and special populations. J Heart Lung Transplant. 2020;39:1050-1069.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436-1446.
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008.